|
Gender, male/ female
|
70/ 34
|
48/ 24
|
22.1/ 19
|
0.8936
| | | |
|
Age, < 60/ ≥60
|
33/ 71
|
19/ 53
|
27.4/ 18.5
|
0.0836
| | | |
|
Serum CA199 (U/ml)
|
|
< 39, ≥39
|
17/ 67
|
10/ 48
|
20.0/ 12.7
|
0.348
| | | |
|
≥ 39, ≥1000
|
67/ 20
|
48/ 14
|
12.7/ 11.0
|
0.543
| | | |
|
< 39, ≥1000
|
17/ 20
|
10/ 14
|
20.0/ 11.0
|
0.078
| | | |
|
Location, head/ body or tail
|
70/ 34
|
49/ 23
|
20/ 16.9
|
0.4537
| | | |
|
Diameter, ≤4/ > 4
|
81/ 23
|
51/ 21
|
25.3/ 9.1
|
< 0.0001****
|
1.594
|
1.224–2.075
|
0.001**
|
|
Histological grade, I, I-II/ II, II-III, III
|
65/ 39
|
44/ 28
|
21.9/ 19.2
|
0.7374
| | | |
|
Microscopic vascular invasion, absent/ present
|
33/ 71
|
19/ 53
|
30.3/ 18.2
|
0.0146*
| | |
0.537
|
|
Microscopic nerve invasion, absent/ present
|
12/ 92
|
8/ 64
|
22.4/ 19.8
|
0.9094
| | | |
|
T stage, T1, 2/ T3, 4
|
57/ 47
|
34/ 38
|
27.6/ 12.9
|
0.0004***
| | |
0.204
|
|
N stage, N0/ N1,2
|
47/ 57
|
30/ 42
|
25.3/ 18.2
|
0.07
| | | |
|
M stage, M0/ M1
|
102/ 2
|
70/ 2
|
20/ 13.6
|
0.2423
| | | |
|
Clinical stage, I-IIa/ IIb-IV
|
35/ 69
|
19/ 53
|
30.3/ 18.2
|
0.0051**
|
2.127
|
1.235–3.665
|
0.007**
|
|
circNEIL3 expression, low/ high
|
52/ 52
|
29/ 43
|
28.4/ 15.3
|
0.0002***
|
1.995
|
1.225–3.248
|
0.006**
|
|
miR-432-5p expression, low/ high
|
52/ 52
|
40/ 32
|
14.8/ 26.1
|
0.0059**
| | |
0.137
|
|
ADAR1 expression, low/ high
|
52/ 52
|
32/ 40
|
25.4/ 13.4
|
0.0023**
|
1.765
|
1.079–2.889
|
0.024*
|
